Healthcare provider profile · identity verified

Julio Cesar Arnau Gonzalez, M.D.

Family Practice · CHICAGO, IL · NPI 1982994679

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1418	437
Amlodipine Besylate	Amlodipine Besylate	567	170
Metformin Hcl	Metformin Hcl	548	170
Alendronate Sodium	Alendronate Sodium	522	167
Lisinopril	Lisinopril	511	155
Levothyroxine Sodium	Levothyroxine Sodium	438	121
Losartan Potassium	Losartan Potassium	413	131
Omeprazole	Omeprazole	371	148
Rosuvastatin Calcium	Rosuvastatin Calcium	339	125
Tamsulosin Hcl	Tamsulosin Hcl	288	100
Ezetimibe	Ezetimibe	286	105
Baclofen	Baclofen	280	144
Glipizide	Glipizide	273	85
Metoprolol Succinate	Metoprolol Succinate	237	79
Gabapentin	Gabapentin	225	95
Fluticasone Propionate	Fluticasone Propionate	196	102
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	173	55
Glipizide Er	Glipizide	172	60
Hydrochlorothiazide	Hydrochlorothiazide	161	49
Pantoprazole Sodium	Pantoprazole Sodium	121	58
Diclofenac Sodium	Diclofenac Sodium	116	65
Finasteride	Finasteride	109	34
Pioglitazone Hcl	Pioglitazone Hcl	109	40
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	103	34
Albuterol Sulfate Hfa	Albuterol Sulfate	101	42
Furosemide	Furosemide	93	34
Trazodone Hcl	Trazodone Hcl	83	37
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	80	28
Allopurinol	Allopurinol	76	24
Ozempic	Semaglutide	76	24
Metformin Hcl Er	Metformin Hcl	74	25
Naproxen	Naproxen	74	34
Sertraline Hcl	Sertraline Hcl	70	22
Metoprolol Tartrate	Metoprolol Tartrate	68	20
Tizanidine Hcl	Tizanidine Hcl	67	35
Montelukast Sodium	Montelukast Sodium	65	21
Trulicity	Dulaglutide	65	20
Carvedilol	Carvedilol	62	21
Pravastatin Sodium	Pravastatin Sodium	59	19
Escitalopram Oxalate	Escitalopram Oxalate	58	19
Januvia	Sitagliptin Phosphate	56	20
Dropsafe Prep Pads	Alcohol Antiseptic Pads	55	21
Eliquis	Apixaban	55	18
Enalapril Maleate	Enalapril Maleate	55	17
Jardiance	Empagliflozin	55	19
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	53	38
Simvastatin	Simvastatin	47	15
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	46	22
Famotidine	Famotidine	42	23
Chlorthalidone	Chlorthalidone	40	13
Mupirocin	Mupirocin	38	19
Spironolactone	Spironolactone	37	11
Triamcinolone Acetonide	Triamcinolone Acetonide	37	22
Hydrocortisone	Hydrocortisone	33	16
Clopidogrel	Clopidogrel Bisulfate	30	12
Droplet Pen Needle	Pen Needle, Diabetic	30	suppressed
Rybelsus	Semaglutide	30	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	28	13
Meclizine Hcl	Meclizine Hcl	28	12
Benazepril Hcl	Benazepril Hcl	27	suppressed
Clonazepam	Clonazepam	27	suppressed
Donepezil Hcl	Donepezil Hcl	27	suppressed
Warfarin Sodium	Warfarin Sodium	26	suppressed
Meloxicam	Meloxicam	25	suppressed
Sildenafil Citrate	Sildenafil Citrate	25	11
Hydroxyzine Hcl	Hydroxyzine Hcl	23	13
Ibuprofen	Ibuprofen	23	13
Glipizide-Metformin	Glipizide/Metformin Hcl	22	suppressed
Nifedipine Er	Nifedipine	22	suppressed
Novolog Flexpen	Insulin Aspart	22	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	22	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Breo Ellipta	Fluticasone/Vilanterol	21	suppressed
Tradjenta	Linagliptin	21	suppressed
Acarbose	Acarbose	20	suppressed
Atenolol	Atenolol	20	suppressed
Flunisolide	Flunisolide	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Potassium Chloride	Potassium Chloride	20	suppressed
Valsartan	Valsartan	20	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Ondansetron Odt	Ondansetron	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	17	suppressed
Tramadol Hcl	Tramadol Hcl	17	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Nabumetone	Nabumetone	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Arnuity Ellipta	Fluticasone Furoate	14	suppressed
Ramipril	Ramipril	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	12
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Fosinopril Sodium	Fosinopril Sodium	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Vascepa	Icosapent Ethyl	13	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	12	suppressed
Fenofibrate	Fenofibrate,micronized	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Trueplus Pen Needle	Pen Needle, Diabetic	12	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	12	11
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Humalog Kwikpen U-200	Insulin Lispro	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error